Biomarker Research (Dec 2024)

AXL in myeloid malignancies – an elusive target?

  • Pia Aehnlich,
  • Katharina Leuchte,
  • Claudia Schöllkopf,
  • Sara Fresnillo Salo,
  • Tina J. Seremet,
  • Estrid Høgdall,
  • Özcan Met,
  • Kirsten Grønbaek,
  • Per thor Straten

DOI
https://doi.org/10.1186/s40364-024-00704-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 5

Abstract

Read online

Abstract The TAM receptor tyrosine kinase family member AXL plays critical roles in tissue homeostasis, survival, chemoresistance, and motility. This study investigates the receptor expression in six AML cell lines and bone marrow myeloblasts from 25 patients with myeloid neoplasms. We found that AXL expression was generally absent or very low in AML myeloblasts. These findings suggest that the efficacy of AXL inhibitors may not depend on AXL positivity but rather on alternative therapeutic mechanisms, such as inducing significant immune responses.

Keywords